On the other hand, based on the tendency observed for the glial protein GMFB in brain EV of subjects with AD (see Fig. 3d—IV) and the positive correlations obtained for this protein between remaining brain AD3 levels versus levels in brain EV from subjects with AD4 and AD6, we can assume that encapsulation of GMFB in EV represents a preclinical potentially neuroprotective strategy that gradually decays over the clinical course of AD (Table 1). The gene discussed is PSEN2; the disease is Alzheimer disease.